Construction Materials

SHM released FY2025 Q4 earnings on April 28 During-Market (BJT), actual revenue CNY 288.63 M, actual EPS CNY 0.0062

SHM released FY2026 Q1 earnings on April 28 Pre-Market (BJT), actual revenue CNY 267.45 M, actual EPS CNY 0.08

SHM released FY2025 annual earnings on April 28 During-Market (BJT), actual revenue CNY 1.206 B (forecast CNY 1.968 B), actual EPS CNY 0.54 (forecast CNY 2.67)

SHM to Release FY2025 Earnings on April 29 During-Market (BJT), Forecast Revenue CNY 1.968 B, EPS CNY 2.67

SHM FY2026 Q1 Earnings Release Scheduled for April 29, Pre-Market BJT

SHM released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 287.68 M, actual EPS CNY 0.2213

SHM released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 916.88 M, actual EPS CNY 0.3877

SHM to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

SHM released FY2025 Semi-Annual earnings on August 29 During-Market (BJT), actual revenue CNY 629.2 M, actual EPS CNY 0.17

SHM released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 304.21 M, actual EPS CNY 0.0163

SHM to Release FY2025 Semi-Annual Earnings on August 30, 2025 (BJT)

Sichuan Double Horse Indicates Fund Focus on Brain-Computer Interface Sector

Sichuan Shuangma Secretary Introduces Company's Pharmaceutical Business

Sichuan Dabeige Completes Share Repurchase

CITIC Financial Assets and Zhongrong Life Plan to Reduce Holdings in Sichuan Shuangma

Sichuan Shuang 马 Major Shareholders Plan to Reduce Shareholding

Guokin Securities Issues Buy Rating Report on Sichuan Shuangma

Sichuan Shuangma Responds to Key Investment Areas in H1

Sichuan Shuang 马 Responds to Solid State Battery Investment

Guangdong Jianxiang Biotechnology Co., Ltd Established

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

CCRMM

Longquan Pipe Industry

Huaxin Building Materials

ORIENTAL YUHONG

SHANGFENG CEMENT

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

000935

According to the Zhitong Finance APP, Sichuan Shuangma released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 917 million yuan, a year-on-year increase of 23.21%. The net profit attributable to shareholders of the listed company was 294 million yuan, a year-on-year increase of 20.03%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 326 million yuan, a year-on-year increase of 46.89%

Zhitong

SHM released its performance for the first three quarters, with a net profit attributable to the parent company of 294 million yuan, a year-on-year increase of 20.03%

Sichuan Shuangma's subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. recently received approval from the National Medical Products Administration to market the chemical raw material drug Acetate Leuprolide. This drug is a Gonadotropin-Releasing Hormone (GnRH) agonist, primarily used for the treatment of endometriosis, uterine fibroids, prostate cancer, and other diseases

SHM: The application for the listing of acetic acid leuprolide chemical raw materials has been approved

Sichuan Shuangma's subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. underwent an on-site inspection by the Russian drug inspection agency from July 30 to August 1, 2025, and recently received the GMP certificate issued by the Ministry of Industry and Trade of the Russian Federation, confirming its compliance with the Good Manufacturing Practices of the Eurasian Economic Union

SHM's subsidiary Hubei Jianxiang has obtained the Russian GMP certificate

On the evening of August 29th, SHM announced that its wholly-owned subsidiary, Shuangma Yibin, obtained the exploration rights for the limestone mine in the Bijia Mountain mining area of Gongxian County, Yibin City, Sichuan Province in July 2003, and completed the "exploration to mining" transition to obtain the mining license for the Bijia Mountain limestone mine in November 2006. According to relevant regulations, Shuangma Yibin is expected to pay a mining rights transfer income of 52.1937 million yuan. Shuangma Yibin will bear the cost of this mining rights transfer income, which is expected to reduce the company's operating profit by 52.1937 million yuan this year

SHM: The subsidiary is expected to pay mining rights transfer income of 52.1937 million yuan

SHM announced that in the first half of 2025, the operating revenue was 629 million yuan, a year-on-year increase of 30.42%. The net profit was 129 million yuan, a year-on-year increase of 13.42%

SHM: Net profit of 129 million yuan in the first half of 2025, a year-on-year increase of 13.42%

Sichuan Harmony Shuangma's shareholder Zhongrong Life Insurance Co., Ltd. reduced its holdings by 6,299,903 shares through centralized bidding transactions from August 4 to 18, 2025, accounting for 0.8252% of the total share capital. After the reduction, Zhongrong Life's holdings decreased to 45,619,267 shares, accounting for 5.9755% of the total share capital. This reduction aligns with its operational needs and pre-disclosure plan and has not yet been fully implemented

SHM: Shareholder Zhongrong Life Insurance reduced its holdings by 1% multiples

On August 13th, SHM stated on the interactive platform that the funds in which the company has invested focus on technology companies related to brain-computer interface. If there is any information that needs to be disclosed, the company will fulfill its information disclosure obligations in accordance with regulations

SHM: The funds they invested in focus on technology companies related to brain-computer interface

000401

002596

605122

600802

000789

The cement sector fluctuated and weakened, with Hainan Ruize hitting the limit down, followed by declines in SIFANG NEW MATERIAL, FJC, Wannianqing, Jidong Cement, Shangfeng Cement, and SHM

BBMG JIDONG

Hainan Ruize

SIFANG NEW MATERIAL

Wannianqing

02799

SHM fell over 5%, CITIC FAMC and Zhongrong Life Insurance plan to collectively reduce their holdings by no more than 2.91% of the company's shares

CITIC FAMC

603093

001236

03678

600927

The diversified financial sector adjusted in the morning, with NANHUA FUTURES hitting the limit down, followed by declines in HOLLY FUTURES, Yongan Futures, Cuiwei Co., Ltd., and SHM

NANHUA FUTURES

Holly Futures

HOLLY FUTURES

Yongan Futures

The diversified financial sector adjusted in the morning, and NANHUA FUTURES hit the limit down

SHM(000935.SZ)

Financial Score

Valuation analysis

Institutional View & Shareholder

Analyst Ratings

SHM released its performance for the first three quarters, with a net profit attributable to the parent company of 294 million yuan, a year-on-year increase of 20.03%

SHM: The application for the listing of acetic acid leuprolide chemical raw materials has been approved

SHM's subsidiary Hubei Jianxiang has obtained the Russian GMP certificate

SHM: The subsidiary is expected to pay mining rights transfer income of 52.1937 million yuan

SHM: Net profit of 129 million yuan in the first half of 2025, a year-on-year increase of 13.42%